London (PRWEB) December 04, 2013
Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics.
Vaniprevir, formerly MK-7009, is an HCV therapy being developed by Merck. Vaniprevir is a protease inhibitor. The HCV protease is required for viral polyprotein processing, which makes the enzyme essential for HCV replication (Asselah and Marcellin, 2013). Inhibitors of the HCV protease are, therefore, attractive antiviral drugs.
-Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on Vaniprevir including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for Vaniprevir for the top nine countries from 2012 to 2022.
-Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.
Reasons to buy
-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis C
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of Vaniprevir performance
-Obtain sales forecast for Vaniprevir from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China).
1 Table of Contents
Copyright©2012 Vocus, Inc.
All rights reserved